REGN · NASDAQ · STOCK
Regeneron Pharmaceuticals (REGN) Stock Analysis
$833.92
52W $541.00 – $847.00
60/100
$85.92B
19.9
0.24
Is REGN Bullish or Bearish?
Bullish.
Innellis AI committee rates Regeneron Pharmaceuticals (REGN) Buy with a composite score of 60/100
, based on 6 analysts with 50% agreement.
Last updated August 23, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.39 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.61 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock — Risk
Bear Case
- RSI at 76 is in overbought territory — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
- Weekly RSI at 79 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.4% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 23, 2026
Overall Committee Score
60/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 40%
of 192 Healthcare peers
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
51
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 76 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock
− Bollinger bandwidth of 24.4% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
54
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 59.6 to 59.6.
Comparing 2026-08-22 to 2026-08-23 (1 day apart).
Technical Analysis
RSI (14)
76.2
Overbought
MACD Histogram
2.149
Bullish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Mixed
Support
$728.73
Resistance
$1209.68
Bollinger %B
0.80
Inside Bands
Price vs Moving Averages
EMA 9
$812.98
Above
EMA 21
$776.61
Above
EMA 50
$728.98
Above
EMA 200
$703.92
Above
Fundamental Analysis
Valuation
54
Growth
79
Profitability
93
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
19.9×
P/B Ratio
2.72×
PEG Ratio
63.96
Dividend Yield
0.44%
52W High
$847.00
52W Low
$541.00
Quality & Growth
ROE
1441.2%
ROA
1110.7%
Gross Margin
8485.9%
Operating Margin
2555.6%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of 19.9 (inexpensive relative to a 15-40x range); Price-to-book of 2.7x; PEG ratio of 64.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.4%; Return on assets of 11.1%; Net margin of 27.9%; Gross margin of 84.9%; Current ratio of 3.34 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow per share is positive (34.06); Most recent quarter beat estimates by 36.5%; 5 consecutive earnings beats; EPS growth accelerating (-17.2% -> +50.9% QoQ); Average YoY EPS growth of 10.9%; Analyst estimates falling over recent quarters
Get the Full REGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →